Engineered Antimicrobial Peptides and Usage Thereof

A method for treating or preventing periprosthetic joint infection in a patient in need thereof, wherein a prosthetic joint is implanted in said patient;

• the method comprising administering:
• (i) a pharmaceutical composition comprising:
• (a) a peptide or pharmaceutically acceptable salt thereof, wherein said peptide has at least 70% sequence identity to a polypeptide sequence of:
• SA-5 (SEQ ID NO:
• 1);
• LSA-5 (SEQ ID NO:
• 2);
• WLSA-5 (SEQ ID NO:
• 3);
• LBU-1 (SEQ ID NO:
• 4);
• LBU-2 (SEQ ID NO:
• 5);
• LBU-3 (SEQ ID NO:
• 6);
• LBU-3.5 (SEQ ID NO:
• 7);
• LBU-4 (SEQ ID NO:
• 8);
• WLBU-1 (SEQ ID NO:
• 9);
• WLBU-2 (SEQ ID NO:
• 10);
• WLBU-3 (SEQ ID NO:
• 11);
• WLBU-4 (SEQ ID NO:
• 12);
• WR6 (SEQ ID NO:
• 13);
• WR12 (SEQ ID NO:
• 14);
• WR18 (SEQ ID NO:
• 15);
• or WR 24 (SEQ ID NO:
• 16);
• and
• (b) an aqueous carrier;
• wherein said pharmaceutical composition is in a form of a liquid, wherein said pharmaceutical composition is locally administered to said prosthetic joint in vivo;
• and
• (ii) an antibiotic or pharmaceutically acceptable salt thereof;
• and
• wherein administration of said pharmaceutical composition and said antibiotic reduces a bacterial burden of said periprosthetic joint infection to a greater extent as compared to administering (i) or (ii) alone.